Home › Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL (posaconazole)
 

Keywords :   


Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL (posaconazole)

2013-04-10 14:30:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION N.J. WHITEHOUSE STATION N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA). Language:  English Contact HTML:  MerckMedia:Pam Eisele, (908) 423-5042Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: the application drug acceptance

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
More »